Hospital
Douglas, Grant, Lincoln & Okanogan Counties Public Hospital District 6
Douglas, Grant, Lincoln & Okanogan Counties Public Hospital District 6 was paid $11.57M by Medicaid between Jan 2018 and Dec 2024, across 112 billing codes. Its largest line is 99284, emergency room visit (serious) — 15% of everything it billed.
33Billing provider infoDOUGLAS, GRANT, LINCOLN & OKANOGAN COUNTIES PUBLIC HOSPITAL DISTRICT 6
GRAND COULEE, WA 99133
GRAND COULEE, WA 99133
33aNPI1184844185assigned 05/01/2007
33bProvider typeCritical Access Hospital
28Total paid$11.57M
24GClaims110,372
24DCodes billed112
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Washington
Rank by total paid#12 of 30
Median peer was paid$9.10M
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 12,904 | $822K | |
| 2019 | 13,672 | $1.07M | |
| 2020 | 9,986 | $756K | |
| 2021 | 19,613 | $1.78M | |
| 2022 | 20,911 | $2.75M | |
| 2023 | 19,046 | $2.45M | |
| 2024incomplete | 14,240 | $1.94M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 3,012 | 2,358 | $1.76M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 4,684 | 4,051 | $1.70M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.9% | 1,220 | 982 | $1.14M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 6.9% | 3,430 | 3,025 | $804K |
| 80053 | Comprehensive metabolic panel | 5.2% | 8,026 | 6,629 | $601K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.5% | 494 | 454 | $526K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.7% | 9,627 | 7,958 | $426K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.9% | 2,448 | 2,268 | $335K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.1% | 2,255 | 1,762 | $245K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.1% | 4,915 | 1,826 | $239K |
| 36415 | Collection of venous blood by venipuncture | 2.0% | 9,619 | 8,271 | $228K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.8% | 2,128 | 1,649 | $213K |
100 more codes
| 80306 | 1.5% | 1,365 | $171K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 1.4% | 849 | $166K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.4% | 525 | $163K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.3% | 1,944 | $152K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.3% | 1,884 | $151K |
| G0378 | Hospital observation service, per hour | 1.3% | 36 | $147K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.2% | 2,636 | $135K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.1% | 2,480 | $124K |
| 71046 | Radiologic examination, chest; 2 views | 1.0% | 1,270 | $121K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.0% | 1,969 | $120K |
| 80061 | Lipid panel | <1% | 1,610 | $103K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,350 | $100K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 854 | $96K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,061 | $81K |
| 81001 | <1% | 3,515 | $75K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,169 | $75K |
| 87486 | <1% | 525 | $63K | |
| 83690 | <1% | 1,093 | $61K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 156 | $59K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 766 | $58K |
| 87581 | <1% | 525 | $58K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,461 | $54K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 513 | $50K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 581 | $49K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 579 | $49K |
| 86140 | <1% | 1,509 | $49K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 508 | $49K |
| 84484 | <1% | 810 | $42K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 407 | $38K |
| 87186 | <1% | 725 | $37K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 374 | $36K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 601 | $35K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,154 | $34K |
| 97161 | <1% | 368 | $33K | |
| 83735 | <1% | 695 | $32K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,619 | $31K |
| 81003 | <1% | 1,085 | $30K | |
| 83880 | <1% | 215 | $28K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 97 | $28K |
| 83605 | <1% | 536 | $25K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 368 | $25K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 856 | $23K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,037 | $22K |
| 84439 | <1% | 368 | $20K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 345 | $18K |
| 85652 | <1% | 626 | $16K | |
| 71045 | Radiologic examination, chest; single view | <1% | 350 | $16K |
| 81025 | <1% | 483 | $15K | |
| 84145 | <1% | 72 | $13K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 23 | $12K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,026 | $12K |
| 87536 | <1% | 67 | $11K | |
| 97035 | <1% | 535 | $11K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 118 | $10K |
| 82962 | <1% | 841 | $10K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 115 | $9K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,560 | $9K |
| 97010 | <1% | 916 | $9K | |
| 84703 | <1% | 168 | $8K | |
| 82728 | <1% | 151 | $7K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 132 | $7K |
| 85027 | <1% | 116 | $6K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 93 | $5K |
| 85610 | <1% | 203 | $4K | |
| 82805 | <1% | 32 | $4K | |
| 82652 | <1% | 95 | $4K | |
| 87070 | <1% | 40 | $3K | |
| 82607 | <1% | 63 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,102 | $3K |
| 87205 | <1% | 73 | $3K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 273 | $2K |
| 96376 | <1% | 44 | $2K | |
| 97602 | <1% | 47 | $2K | |
| 86803 | <1% | 44 | $2K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 55 | $2K |
| Q3014 | Telehealth originating site facility fee | <1% | 88 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 106 | $2K |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 38 | $1K |
| 82570 | <1% | 31 | $1K | |
| J2704 | Injection, propofol, 10 mg | <1% | 158 | $1K |
| 87077 | <1% | 14 | $914.79 | |
| 36416 | <1% | 35 | $711.76 | |
| 86780 | <1% | 16 | $686.45 | |
| 87480 | <1% | 12 | $666.97 | |
| 85379 | <1% | 15 | $652.41 | |
| 87340 | <1% | 14 | $532.78 | |
| 87510 | <1% | 12 | $510.39 | |
| 87899 | <1% | 26 | $441.40 | |
| 87088 | <1% | 17 | $312.07 | |
| 86901 | <1% | 13 | $266.76 | |
| 81015 | <1% | 103 | $265.45 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 28 | $167.05 |
| 95250 | <1% | 19 | $67.74 | |
| A9270 | Non-covered item or service | <1% | 185 | $60.98 |
| 96127 | <1% | 33 | $59.10 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 13 | $56.02 |
| 87806 | <1% | 26 | $48.48 | |
| 80320 | 0% | 548 | $0.00 | |
| 80329 | 0% | 30 | $0.00 | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | 0% | 78 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHUGHES, KELLY (CEO)
| Provider | Location | Paid |
|---|---|---|
| Douglas, Grant, Lincoln & Okanogan Counties Public Hospital District 6 | Coulee City, WA | $323K |
| Douglas, Grant, Lincoln & Okanogan Counties Public Hospital District 6 | Grand Coulee, WA | $163K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.